Phase 3 SELENE study: ibrutinib plus BR/R-CHOP in previously treated patients with follicular or marginal zone lymphoma

Nastoupil, LJ; Hess, G; Pavlovsky, MA; Danielewicz, I; Freeman, J; Garcia-Sancho, AM; Glazunova, V; Grigg, A; Hou, JZ; Janssens, A; Kim, SJ; Masliak, Z; Mckay, P; Merli, F; Munakata, W; Nagai, H; Özcan, M; Preis, M; Wang, TY; Rowe, M; Tamegnon, M; Cir, R; Henninger, T; Curtis, M; Caces, DB; Thieblemont, C; Salles, G

Nastoupil, LJ (通讯作者)，Univ Texas MD Anderson Canc Ctr, Dept Lymphoma Myeloma, 1515 Holcombe Blvd, Houston, TX 77030 USA.

BLOOD ADVANCES, 2023; 7 (22): 7141

Abstract

The phase 3 SELENE study evaluated ibrutinib + chemoimmunotherapy (CIT; bendamustine and rituximab [BR]; or rituximab, cyclophosphamide, doxorubicin, ......

Full Text Link


Links

期刊讨论 | 中国SCI论文 | 期刊主页 | 投稿经验 | 杂志官网 | 投稿链接 | 作者需知 | PMC链接 | Pubmed全文检索